AB Corporate Bond ETF (NASDAQ:EYEG) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened

AB Corporate Bond ETF (NASDAQ:EYEG) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $35.56 and traded as low as $35.31. AB Corporate Bond ETF shares last traded at $35.3150, with a volume of 42 shares trading hands.

AB Corporate Bond ETF Stock Up 0.0%

The stock has a 50-day simple moving average of $35.26 and a two-hundred day simple moving average of $35.56. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.01. The firm has a market cap of $28.25 million, a PE ratio of -21.02 and a beta of 0.17.

AB Corporate Bond ETF Increases Dividend

The company also recently disclosed a monthly dividend, which was paid on Thursday, June 4th. Stockholders of record on Monday, June 1st were given a dividend of $0.1415 per share. This is a boost from AB Corporate Bond ETF’s previous monthly dividend of $0.14. The ex-dividend date was Monday, June 1st. This represents a c) annualized dividend and a dividend yield of 4.8%. AB Corporate Bond ETF’s dividend payout ratio is currently -102.98%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in EYEG. Kestra Advisory Services LLC bought a new stake in shares of AB Corporate Bond ETF in the 4th quarter worth approximately $34,000. Jane Street Group LLC grew its holdings in shares of AB Corporate Bond ETF by 166.7% during the 4th quarter. Jane Street Group LLC now owns 15,741 shares of the specialty pharmaceutical company’s stock valued at $563,000 after purchasing an additional 9,839 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in shares of AB Corporate Bond ETF by 32.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock valued at $5,634,000 after purchasing an additional 38,685 shares during the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.